ライフサイエンスコーパス: B-cell acute lymphoblastic leukemia

1 2-dependent myeloproliferative neoplasms and B cell acute lymphoblastic leukemia.

2 response in a phase 1 trial for treatment of B cell acute lymphoblastic leukemia.

3 sociated with nearly one-fourth of pediatric B cell acute lymphoblastic leukemia.

4 syndrome as well as in t(12;21) in childhood B cell acute lymphoblastic leukemia.

5 y the t(1;19) translocation in pediatric pre-B cell acute lymphoblastic leukemia.

6 lymphoid blast crisis or abolish established B-cell acute lymphoblastic leukemia.

7 X5-PML chimeric protein in two patients with B-cell acute lymphoblastic leukemia.

8 ) chromosomal translocation of childhood pre-B-cell acute lymphoblastic leukemia.

9 st frequent translocation found in pediatric B-cell acute lymphoblastic leukemias.

10 iagnoses included 28 non-Hodgkin lymphoma, 4 B-cell acute lymphoblastic leukemia, 1 Hodgkin disease,

11 defined CD4+:CD8+ composition to adults with B cell acute lymphoblastic leukemia after lymphodepletio

12 Childhood CD19(+)CD10(-) pro-B cell acute lymphoblastic leukemia (ALL) is thought to

13 fficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and chronic ly

14 Therapeutic options for advanced B-cell acute lymphoblastic leukemia (ALL) and chronic ly

15 translocation t(6;12)(q23;13) in a childhood B-cell acute lymphoblastic leukemia (ALL) cell line fuse

16 hormones induce apoptosis in T-cell and pre-B-cell acute lymphoblastic leukemia (ALL) cells.

17 cell death in normal pre-B cells and in pre-B-cell acute lymphoblastic leukemia (ALL) driven by BCR-

18 ronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have enroll

19 en established from a patient with precursor-B-cell acute lymphoblastic leukemia (ALL), which exhibit

20 f the pathogenesis of CNS involvement in pre-B-cell acute lymphoblastic leukemia (ALL).

21 monocytic leukemia, myelodysplasic syndrome, B-cell acute lymphoblastic leukemia, and acute myelogeno

22 to impaired B cell development, followed by B cell acute lymphoblastic leukemia at 100% incidence an

23 eukemia (CML) in chronic phase but not Ph(+) B cell acute lymphoblastic leukemia (B-ALL) and CML blas

24 B cell acute lymphoblastic leukemia (B-ALL) is frequentl

25 ment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearran

26 syndrome confers a 20-fold increased risk of B cell acute lymphoblastic leukemia (B-ALL), and polysom

27 nt effects in relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but antigen

28 outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL).

29 elate with poor prognosis in human precursor B cell acute lymphoblastic leukemia (B-ALL).

30 , also plays an important role in pre-BCR(+) B cell acute lymphoblastic leukemia (B-ALL).

31 cription factor STAT5 has a critical role in B cell acute lymphoblastic leukemia (B-ALL).

32 signaling, including the high-risk subset of B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2

33 Infant B-cell acute lymphoblastic leukemia (B-ALL) accounts for

34 includes chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL) and is induc

35 We treated 7 patients with B-cell acute lymphoblastic leukemia (B-ALL) harboring re

36 ority of treatment failures in patients with B-cell acute lymphoblastic leukemia (B-ALL) receiving al

37 The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor

38 acute lymphoblastic leukemia (T-ALL) and (3) B-cell acute lymphoblastic leukemia (B-ALL) samples, (c)

39 B-cell acute lymphoblastic leukemia (B-ALL), more freque

40 ic strategies, particularly in diseases like B-cell acute lymphoblastic leukemia (B-ALL), where few t

41 therapy is much less effective against Ph(+)B-cell acute lymphoblastic leukemia (B-ALL).

42 nction indicates poor prognosis in precursor B-cell acute lymphoblastic leukemia (B-ALL).

43 vation occurs frequently in human progenitor B-cell acute lymphoblastic leukemia (B-ALL).

44 1 (Ebf1) during early B-cell development and B-cell acute lymphoblastic leukemia (B-ALL).

45 se 2 (CK2) to eradicate disease in high-risk B-cell acute lymphoblastic leukemia (B-ALL).

46 ith chronic myeloid leukemia (CML) and Ph(+) B-cell acute lymphoblastic leukemia (B-ALL).

47 BET class of human bromodomain proteins, in B-cell acute lymphoblastic leukemia (B-ALL).

48 However, they are not efficient in Ph+ B-cell acute lymphoblastic leukemia (B-ALL).

49 less effective in CML blast crisis or Ph(+) B-cell acute lymphoblastic leukemia (B-ALL).

50 Approximately 10% of B-cell acute lymphoblastic leukemias (B-ALLs) overexpres

51 We investigated DNA methylomes of pediatric B-cell acute lymphoblastic leukemias (B-ALLs) using whol

52 eration of secondary genetic events in human B-cell acute lymphoblastic leukemias (B-ALLs), illustrat

53 e a significant effect on the development of B-cell acute lymphoblastic leukemia (BALL) induced by BC

54 e suitability of targeting CD22 on precursor B-cell acute lymphoblastic leukemia (BCP-ALL), lymphobla

55 BCR-ABL1(+) precursor B-cell acute lymphoblastic leukemia (BCR-ABL1(+) B-ALL)

56 d blood cancers and primary, patient-derived B-cell acute lymphoblastic leukemia blasts compared with

57 se of patients suffering from T-cell and pre-B-cell acute lymphoblastic leukemia by increasing steroi

58 R-125b is also up-regulated in patients with B-cell acute lymphoblastic leukemia carrying the t(11;14

59 he t(17;19) chromosomal translocation in pro-B-cell acute lymphoblastic leukemia, incorporates the tr

60 usion protein in t(17;19)-positive human pro-B cell acute lymphoblastic leukemias is believed to prom

61 lar results were obtained in human precursor B-cell acute lymphoblastic leukemia lines when Notch act

62 marrow commonly occurs in T-ALL and relapsed B-cell acute lymphoblastic leukemia patients, and is ass

63 Philadelphia chromosome (Ph)-like B-cell acute lymphoblastic leukemia (Ph-like ALL) is ass

64 Here, human pre-B cell acute lymphoblastic leukemia (pre-B ALL) was used

65 KZF1) is a hallmark of BCR-ABL1(+) precursor B cell acute lymphoblastic leukemia (pre-B ALL).

66 Some cases of pre-B cell acute lymphoblastic leukemia (pre-B-ALL) are caus

67 rafts from pediatric patients with precursor B-cell acute lymphoblastic leukemia (pre-B ALL) in NSG m

68 BX1 (E2A-PBX1)-frequently found in precursor-B-cell acute lymphoblastic leukemia (preB-ALL), we devel

69 nsposon screens of 123 mammary tumors and 20 B-cell acute lymphoblastic leukemias, respectively.

70 Among these mice, half died of B-cell acute lymphoblastic leukemia, T-cell acute lympho

71 l evolution of a form of childhood precursor-B cell acute lymphoblastic leukemia that is characterize

72 me-positive chronic myelogenous leukemia and B cell acute lymphoblastic leukemia through the inhibiti

73 tive acute lymphoblastic leukemia and mature B-cell acute lymphoblastic leukemia using biologically t

74 1-induced CML-like MPN and the appearance of B-cell acute lymphoblastic leukemia, whereas complete de

75 patients with acute myelogenous leukemia and B-cell acute lymphoblastic leukemia whose tumors harbor

76 and effector function of human NK cells in a B-cell acute lymphoblastic leukemia xenotransplants mode